AbbVie researches, develops, and commercializes biopharmaceutical products primarily in the fields of immunology, oncology, neuroscience, and eye care. Building on its heritage with the blockbuster drug Humira, the company maintains a portfolio of specialty medicines and an active pipeline targeting immune-mediated diseases, cancers, and neurological disorders. Its products are prescribed by physicians and delivered through healthcare systems to patients worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 15,423 | — | 928 | — |
| Q3 2025 | 15,776 | — | 176 | — |
| Q4 2025 | 16,618 | — | 1,806 | — |
| Q1 2026 | 15,002 | — | 685 | — |
| Q2 2026 | 16,990 | 10.2% | 3,601 | 288% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Chevron Corporation (CVX), The Coca-Cola Company (KO), Oracle Corporation (ORCL), The Procter & Gamble Company (PG), UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK)